The transactions highlighted below are representative of Greenhill engagements. In addition, the Firm has completed many engagements that were not publicly-disclosed.
.
Recent Transactions
Sort By
04-Sep-23
Pending
$6.6 billion AUD
Target:
Liontown Resources Limited
Acquiror:
Albemarle Corporation
Advising Australian-based lithium company Liontown Resources Limited on its response to change of control proposals from Albemarle Corporation.
15-Aug-23
Pending
Undisclosed
Target:
ElectraMeccanica
Acquiror:
Tevva
Advising ElectraMeccanica, a North American designer and assembler of electric vehicles, on its all-stock merger with Tevva, a UK-based market leader in zero emission electric medium- and heavy-duty commercial vehicles
10-Aug-23
Undisclosed
Target:
Clinigen Ltd’s portfolio of Established Medicines
Acquiror:
CNX Therapeutics
Advised Clinigen Ltd, a UK-based global pharmaceutical services company and portfolio company of Triton Partners, on the sale of a portfolio of Established Medicines to CNX Therapeutics, a UK-based European pharma company owned by Inflexion Partners
13-Jul-23
$224 million
Target:
Distribuidora Internacional Carmen SAU
Acquiror:
Diploma PLC
Advised Diploma PLC in the acquisition of Distribuidora Internacional Carmen SAU (“DICSA”), a market-leading distributor of fluid power solutions into the European aftermarket
01-Jun-23
$90.4 million
Target:
PCAS Canada Inc.
Acquiror:
DIC Corporation
Advised DIC Corporation, a Japanese specialty chemical company, on the acquisition of PCAS Canada Inc., a contract manufacturer of high-quality photoresist polymers, from PCAS SA, a French manufacturer of complex molecules for Life Sciences and Specialty Chemicals markets which is a majority-owned subsidiary of SK Capital-backed Seqens
27-Apr-23
$403 million
Target:
Distrelec BV
Acquiror:
RS Group plc
Advised RS Group plc on the acquisiton of Distrelec, a high-service, digital-led distributor of industrial MRO and electronic products
25-Apr-23
Pending
Undisclosed
Target:
Kyowa Kirin International’s testosterone replacement therapy drug, Tostran®
Acquiror:
Advanz Pharma (UK)
Advising Kyowa Kirin International, a subsidiary of Kyowa Kirin Co., Ltd, a Japanese global specialty pharma company, on the divestiture of its testosterone replacement therapy drug, Tostran®, to Advanz Pharma, a privately-held, specialty pharmaceutical company
05-Apr-23
Pending
$185 million
Target:
Calibre Group’s QuadR Business
Acquiror:
WSP Global Inc.
Advising Calibre Group, an Australian diversified engineering group, on the sale of its Calibre QuadR business to WSP Global Inc., a leading global engineering and professional services firm
20-Mar-23
Pending
Undisclosed
Target:
Clinigen Ltd’s Lamda Laboratories
Acquiror:
Adragos Pharma
Advising Clinigen Ltd, a UK-based global pharmaceutical services company and portfolio company of Triton Partners, on the sale of Lamda Laboratories, a European contract development business, to Adragos Pharma, a Munich-based pharmaceutical CDMO
07-Mar-23
Undisclosed
Target:
David Brown Santasalo
Acquiror:
Stellex Capital Management
Advised N4 Partners on the sale of David Brown Santasalo (DBS), UK based industrial gear manufacturer, to Stellex Capital Management
23-Jan-23
Pending
$200 million
Target:
Clinigen Ltd’s Proleukin
Acquiror:
Iovance Biotherapeutics
Advising Clinigen Ltd, a UK-based global pharmaceutical services company and portfolio company of Triton Partners, on the sale of Proleukin (Interleukin-2 (Aldesleukin)), to Iovance Biotherapeutics, a late-stage biotechnology company developing novel T cell-based cancer immunotherapies
30-Dec-22
$153 million
Target:
Annovera®, Imvexxy®, Bijuva®, and prescription prenatal vitamin products
Acquiror:
Mayne Pharma
Advised TherapeuticsMD, Inc., an innovative, leading women’s healthcare company on definitive agreements to license its products to Mayne Pharma
30-Nov-22
Pending
Undisclosed
Target:
Calibre Group’s Built Environment Business
Acquiror:
Egis S.A.
Advised Calibre Group, a leading Australian provider of sustainable engineering solutions, on the sale of its Built Environment business to Egis S.A., a French headquartered global consulting and engineering services firm owned by Tikehau Capital and Caisse des Dépôts
28-Nov-22
Pending
$650 million
Target:
Brambles (CHEP China)
Acquiror:
Loscam Greater China
Adviser to Brambles on the merger of its China business (CHEP China) with Loscam Greater China
24-Nov-22
Pending
Undisclosed
Target:
Kyowa Kirin International’s established medicines business
Acquiror:
Grünenthal
Advising Kyowa Kirin International, a subsidiary of Kyowa Kirin Co., Ltd, a Japanese global specialty pharma company, on a collaboration agreement with Grünenthal GmbH, a global, science-based, privately-owned pharmaceutical company
18-Nov-22
Pending
$6.4 billion
Target:
OZ Minerals Limited
Acquiror:
BHP Group Limited
Advising Australian-based copper company OZ Minerals Limited, on its response to two change of control proposals from BHP Group Limited, the world’s largest diversified resources company
13-Sep-22
Undisclosed
Target:
InterGen N.V.’s UK business
Acquiror:
Bortela Capital s.r.o
Advised InterGen N.V., one of the UK’s largest independent power producers with a portfolio of four gas plants and a pipeline of large-scale battery energy storage system projects, on the sale of its business interests in the UK to CREDITAS Group, a Czech entity ultimately owned by Pavel Hubáček, whose energy division UCED is the fourth largest energy distributor in the Czech Republic
28-Jul-22
Pending
$1.6 billion
Target:
Derco Holdings
Acquiror:
Inchcape Plc
Advising and acting as sponsor to Inchcape plc, the leading independent global automotive distributor, on its proposed Class 1 acquisition of Derco, the largest independent automotive distributor by volume in Latin America
04-Jul-22
$270 million
Target:
Vulcanic
Acquiror:
Spirax-Sarco Engineering plc
Advised Spirax-Sarco Engineering plc, a thermal energy management and niche pumping specialist, on the $270m acquisition of Vulcanic, a French industrial electric heating group and the largest supplier in Europe of bespoke industrial electric heating solutions
30-Jun-22
~$210 million
Target:
Liontown Resources
Acquiror:
Offtake Agreement and Financing Facility from Ford Motor Company
Advised Liontown Resources, an ASX-listed lithium company focused on the development of the world-class Kathleen Valley Lithium Project, on a lithium spodumene concentrate offtake agreement and A$300m financing facility from Ford Motor Company
04-Apr-22
Pending
~$230 million
Target:
DGO Gold
Acquiror:
Gold Road Resources
Advising DGO Gold, an ASX-listed gold exploration company, on its recommended, off-market takeover offer from Gold Road Resources, an ASX-listed gold producer
28-Mar-22
Pending
~$1.4 billion
Target:
Theramex
Acquiror:
Carlyle and PAI Partners
Advising Carlyle, the leading private equity investor, on the acquisition of Theramex, a Women’s health-focused specialty pharmaceutical company . The acquisition was jointly executed with PAI Partners
28-Mar-22
Pending
$105 million
Target:
Acacia Pharma Group plc
Acquiror:
Eagle Pharmaceuticals, Inc.
Advising Acacia, a UK-domiciled and Euronext-listed commercial stage biopharmaceutical company, on the sale to Eagle Pharmaceuticals, an integrated pharmaceutical company with R&D, manufacturing and commercial expertise
16-Feb-22
Undisclosed
Target:
Liontown Resources
Acquiror:
Offtake Agreement with Tesla
Advised Liontown Resources, an ASX-listed lithium company focused on the development of the world class Kathleen Valley Lithium Project, on a lithium spodumene concentrate offtake agreement with Tesla, a major electric vehicle manufacturer
12-Jan-22
Undisclosed
Target:
Liontown Resources
Acquiror:
Offtake Agreement with LG Energy Solutions
Advised Liontown Resources, an ASX-listed lithium company focused on the development of the world class Kathleen Valley Lithium Project, on a lithium spodumene concentrate offtake agreement with LG Energy Solutions, a major South Korean-based EV battery supplier for leading global automakers